We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A prominent U.S. senator has asked the FTC to launch an antitrust investigation into whether Merck is offering rebates to major health insurers that agree to adjust drug copays so it will be cheaper to buy Merck’s cholesterol drug Zocor than the generic equivalent.
The FTC’s proposed study of the economic effects of authorized generics has some interested groups raising such concerns as the impact the practice has on prices, availability and competition.
The FTC has filed a persuasive response to the Department of Justice’s (DOJ) brief urging the Supreme Court not to hear a pivotal antitrust case, according to one former FTC official.
The Solicitor General of the United States is recommending against a Supreme Court review of the FTC’s antitrust case against Schering-Plough — undermining the agency’s effort to kill the practice of “reverse payments,” where drugmakers pay generic competitors to delay launching their version of the innovator’s product.
Andrx and Watson Pharmaceuticals have received a second request from the FTC for additional information in connection with Watson’s impending purchase of Andrx, the companies said May 3.
Boston Scientific received antitrust approval from the Federal Trade Commission (FTC) for its proposed merger with Guidant, Boston Scientific announced April 20.
The FTC has announced it will conduct a study on the competitive effects of authorized generics, the latest in a string of actions that shows the commission is taking a harder line on potentially anticompetitive agreements between drugmakers.
The FTC has announced it will conduct a study on the competitive effects of authorized generics, the latest in a string of actions that shows the commission is taking a harder line on potentially anticompetitive agreements between drugmakers.
The FTC has approved a final consent order allowing the $7.4 billion merger of Teva Pharmaceutical and Ivax to go forward, the commission announced March 8.
The FTC has asked Cephalon for information about settlements it made with four generic drug firms allowing them to market generic versions of Cephalon’s narcolepsy drug Provigil, according to documents filed with the SEC.